Get the Stockscreener App
11.02
2.20%
-0.20
Entrada Therapeutics Inc stock is traded at $11.02, with a volume of 8,936.
It is down -2.20% in the last 24 hours and down -13.12% over the past month.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
See More
Previous Close:
$11.22
Open:
$11.23
24h Volume:
8,936
Relative Volume:
0.08
Market Cap:
$420.31M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
3.723
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
+5.31%
1M Performance:
-13.12%
6M Performance:
-26.84%
1Y Performance:
-13.66%
1-Day Range:
$10.97
$11.36
1-Week Range:
$10.22
$11.36
52-Week Range:
$10.22
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
10.97 | 420.31M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.27 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.83 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.21 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.31 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.51 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
Long Term Trading Analysis for (TRDA) - Stock Traders Daily
Entrada Therapeutics stock hits 52-week low at $10.25 - Investing.com India
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday - Defense World
Entrada Therapeutics stock hits 52-week low at $11.3 amid market shifts - Investing.com Canada
Brokers Offer Predictions for TRDA Q4 Earnings - Defense World
What is William Blair’s Estimate for TRDA Q1 Earnings? - Defense World
Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Simply Wall St
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat
Entrada Therapeutics' (TRDA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating - TipRanks
Entrada Therapeutics reports Q4 EPS 3c vs. (29c) last year - TipRanks
Oppenheimer maintains Entrada stock Outperform with $30 target - Investing.com India
Oppenheimer maintains Entrada stock Outperform with $30 target By Investing.com - Investing.com South Africa
Entrada Therapeutics Reports Strong 2024 Financial Results - TipRanks
Entrada Therapeutics earnings beat by $0.70, revenue fell short of estimates - Investing.com UK
Entrada Therapeutics sees cash runway into 2Q27 - TipRanks
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World
Allspring Global Investments Holdings LLC Lowers Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics Receives Buy Rating Amid Regulatory Progress and Promising Clinical Developments - TipRanks
FDA authorizes Entrada’s DMD drug study By Investing.com - Investing.com Australia
Optimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials - TipRanks
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy - Benzinga
Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket - Marketscreener.com
Entrada rises as FDA removes clinical hold on muscle-wasting therapy - TradingView
FDA authorizes Entrada's DMD drug study - Investing.com India
FDA authorizes Entrada’s DMD drug study - Investing.com
Entrada Therapeutics Receives FDA Approval for DMD Study - TipRanks
FDA authorizes Entrada's DMD drug study By Investing.com - Investing.com South Africa
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 - The Manila Times
Entrada announces FDA removal of clinical hold on ENTR-601-44 - TipRanks
H.C. Wainwright maintains $20 target on Entrada Therapeutics stock - MSN
Trading (TRDA) With Integrated Risk Controls - Stock Traders Daily
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside - Seeking Alpha
Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks - TipRanks
Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now - Insider Monkey
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
How the (TRDA) price action is used to our Advantage - Stock Traders Daily
Entrada Shorted Ohio State Affiliate $20 Million Fees, Suit Says - Bloomberg Law
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - MarketBeat
SG Americas Securities LLC Has $243,000 Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
BlackRock, Inc. Increases Stake in Entrada Therapeutics Inc - GuruFocus.com
Entrada Therapeutics advances Duchenne treatment study - MSN
ENTR-601-44 Trial For DMD Authorized In UK, Study Launch Expected In Q2 2025 - Nasdaq
Entrada Therapeutics Gets UK Approval for Phase 1/2 Study of Duchenne Muscular Dystrophy Treatment - Marketscreener.com
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy - The Manila Times
Duchenne Muscular Dystrophy Breakthrough: Entrada's Novel Treatment Advances After Promising Safety Results - StockTitan
Azenta Announces the Election of Dipal Doshi to its Board of Directors - PR Newswire
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entrada Therapeutics Inc Stock (TRDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Dec 11 '24 |
Sale |
20.23 |
21,787 |
440,751 |
4,381,062 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Dec 10 '24 |
Sale |
20.77 |
22,935 |
476,360 |
4,402,849 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Dec 11 '24 |
Sale |
20.23 |
21,787 |
440,751 |
4,381,062 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Dec 02 '24 |
Option Exercise |
2.10 |
5,000 |
10,500 |
78,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
2.10 |
1,000 |
2,100 |
74,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Dec 02 '24 |
Sale |
20.00 |
5,000 |
99,978 |
73,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Nov 29 '24 |
Sale |
19.97 |
1,000 |
19,970 |
73,849 |
| Sethuraman Natarajan | President, Research & Develop. |
Dec 03 '24 |
Sale |
20.15 |
11,703 |
235,786 |
144,997 |
| Sethuraman Natarajan | President, Research & Develop. |
Dec 02 '24 |
Sale |
20.26 |
4,088 |
82,834 |
156,700 |
| Sethuraman Natarajan | President, Research & Develop. |
Nov 29 '24 |
Sale |
20.00 |
100 |
2,000 |
160,788 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):